Korean Drug Co. Ltd (014570) - Net Assets
Based on the latest financial reports, Korean Drug Co. Ltd (014570) has net assets worth ₩81.04 Billion KRW (≈ $54.92 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩95.05 Billion ≈ $64.41 Million USD) and total liabilities (₩14.01 Billion ≈ $9.50 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 014570 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩81.04 Billion |
| % of Total Assets | 85.26% |
| Annual Growth Rate | 4.82% |
| 5-Year Change | 10.21% |
| 10-Year Change | 57.22% |
| Growth Volatility | 5.61 |
Korean Drug Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Korean Drug Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Korean Drug Co. Ltd (014570) total assets for the complete picture of this company's asset base.
Annual Net Assets for Korean Drug Co. Ltd (2014–2024)
The table below shows the annual net assets of Korean Drug Co. Ltd from 2014 to 2024. For live valuation and market cap data, see Korean Drug Co. Ltd (014570) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩78.11 Billion ≈ $52.93 Million |
+1.32% |
| 2023-12-31 | ₩77.09 Billion ≈ $52.24 Million |
-9.00% |
| 2022-12-31 | ₩84.71 Billion ≈ $57.41 Million |
+10.46% |
| 2021-12-31 | ₩76.69 Billion ≈ $51.97 Million |
+8.21% |
| 2020-12-31 | ₩70.87 Billion ≈ $48.03 Million |
+8.95% |
| 2019-12-31 | ₩65.05 Billion ≈ $44.08 Million |
+3.58% |
| 2018-12-31 | ₩62.80 Billion ≈ $42.56 Million |
+10.23% |
| 2017-12-31 | ₩56.97 Billion ≈ $38.61 Million |
+6.17% |
| 2016-12-31 | ₩53.66 Billion ≈ $36.37 Million |
+8.02% |
| 2015-12-31 | ₩49.68 Billion ≈ $33.67 Million |
+1.82% |
| 2014-12-31 | ₩48.79 Billion ≈ $33.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Korean Drug Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 76.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩70.59 Billion | 90.38% |
| Common Stock | ₩5.50 Billion | 7.04% |
| Other Components | ₩2.01 Billion | 2.58% |
| Total Equity | ₩78.11 Billion | 100.00% |
Korean Drug Co. Ltd Competitors by Market Cap
The table below lists competitors of Korean Drug Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DS Sigma Holdings Berhad
KLSE:0269
|
$30.73 Million |
|
GLOBUS MARITIME DL -004
F:0G93
|
$30.74 Million |
|
Alam Maritim Resources Bhd
KLSE:5115
|
$30.76 Million |
|
Italy Innovazioni SpA
PA:MLITN
|
$30.78 Million |
|
Asuransi Harta Aman Pratama Tbk PT
JK:AHAP
|
$30.72 Million |
|
Qingdao Hengshun Zhongsheng
SHE:300208
|
$30.71 Million |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
$30.71 Million |
|
Nordic Iron Ore
ST:NIO
|
$30.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Korean Drug Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 77,090,083,470 to 78,106,002,540, a change of 1,015,919,070 (1.3%).
- Net income of 2,995,105,180 contributed positively to equity growth.
- Dividend payments of 1,617,996,600 reduced retained earnings.
- Share repurchases of 133,701,860 reduced equity.
- New share issuances of 133,701,860 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.00 Billion | +3.83% |
| Dividends Paid | ₩1.62 Billion | -2.07% |
| Share Repurchases | ₩133.70 Million | -0.17% |
| Share Issuances | ₩133.70 Million | +0.17% |
| Other Changes | ₩-361.19 Million | -0.46% |
| Total Change | ₩- | 1.32% |
Book Value vs Market Value Analysis
This analysis compares Korean Drug Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.85x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4917.69 | ₩4190.00 | x |
| 2017-12-31 | ₩5220.49 | ₩4190.00 | x |
| 2018-12-31 | ₩5759.32 | ₩4190.00 | x |
| 2019-12-31 | ₩5970.82 | ₩4190.00 | x |
| 2020-12-31 | ₩6507.00 | ₩4190.00 | x |
| 2021-12-31 | ₩7111.74 | ₩4190.00 | x |
| 2022-12-31 | ₩7855.41 | ₩4190.00 | x |
| 2023-12-31 | ₩7146.81 | ₩4190.00 | x |
| 2024-12-31 | ₩7222.25 | ₩4190.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Korean Drug Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.10%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.14x
- Recent ROE (3.83%) is below the historical average (6.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 4.41% | 4.74% | 0.73x | 1.27x | ₩-2.73 Billion |
| 2015 | 3.57% | 3.74% | 0.80x | 1.19x | ₩-3.19 Billion |
| 2016 | 9.41% | 9.13% | 0.87x | 1.18x | ₩-316.12 Million |
| 2017 | 8.22% | 8.45% | 0.83x | 1.17x | ₩-1.01 Billion |
| 2018 | 10.45% | 12.61% | 0.71x | 1.16x | ₩282.52 Million |
| 2019 | 5.99% | 7.01% | 0.73x | 1.17x | ₩-2.61 Billion |
| 2020 | 10.38% | 11.02% | 0.80x | 1.18x | ₩272.57 Million |
| 2021 | 11.79% | 12.14% | 0.84x | 1.16x | ₩1.37 Billion |
| 2022 | 13.94% | 14.76% | 0.85x | 1.12x | ₩3.34 Billion |
| 2023 | -6.38% | -6.04% | 0.91x | 1.16x | ₩-12.63 Billion |
| 2024 | 3.83% | 4.10% | 0.82x | 1.14x | ₩-4.82 Billion |
Industry Comparison
This section compares Korean Drug Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $105,982,248,875
- Average return on equity (ROE) among peers: -1.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Korean Drug Co. Ltd (014570) | ₩81.04 Billion | 4.41% | 0.17x | $30.72 Million |
| PharmGen Science Inc (004720) | $228.21 Billion | 2.67% | 0.47x | $62.30 Million |
| Chorokbaem Healthcare Co Ltd (118000) | $18.71 Billion | -15.55% | 0.96x | $242.13 Million |
| BCWORLD PHARM. Co. Ltd (200780) | $79.55 Billion | 0.35% | 1.30x | $30.80 Million |
| Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) | $97.46 Billion | 4.95% | 1.31x | $132.95 Million |
About Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more